JPWO2020041741A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020041741A5
JPWO2020041741A5 JP2021533405A JP2021533405A JPWO2020041741A5 JP WO2020041741 A5 JPWO2020041741 A5 JP WO2020041741A5 JP 2021533405 A JP2021533405 A JP 2021533405A JP 2021533405 A JP2021533405 A JP 2021533405A JP WO2020041741 A5 JPWO2020041741 A5 JP WO2020041741A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
alkyl
compound
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021533405A
Other languages
English (en)
Japanese (ja)
Other versions
JP7579253B2 (ja
JP2021535207A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/047968 external-priority patent/WO2020041741A1/en
Publication of JP2021535207A publication Critical patent/JP2021535207A/ja
Publication of JPWO2020041741A5 publication Critical patent/JPWO2020041741A5/ja
Priority to JP2024187991A priority Critical patent/JP2025020206A/ja
Application granted granted Critical
Publication of JP7579253B2 publication Critical patent/JP7579253B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021533405A 2018-08-24 2019-08-23 甲状腺ホルモン受容体ベータアゴニスト化合物 Active JP7579253B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024187991A JP2025020206A (ja) 2018-08-24 2024-10-25 甲状腺ホルモン受容体ベータアゴニスト化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862722312P 2018-08-24 2018-08-24
US62/722,312 2018-08-24
US201962867117P 2019-06-26 2019-06-26
US62/867,117 2019-06-26
PCT/US2019/047968 WO2020041741A1 (en) 2018-08-24 2019-08-23 Thyroid hormone receptor beta agonist compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024187991A Division JP2025020206A (ja) 2018-08-24 2024-10-25 甲状腺ホルモン受容体ベータアゴニスト化合物

Publications (3)

Publication Number Publication Date
JP2021535207A JP2021535207A (ja) 2021-12-16
JPWO2020041741A5 true JPWO2020041741A5 (enExample) 2022-08-30
JP7579253B2 JP7579253B2 (ja) 2024-11-07

Family

ID=69584321

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021533405A Active JP7579253B2 (ja) 2018-08-24 2019-08-23 甲状腺ホルモン受容体ベータアゴニスト化合物
JP2024187991A Pending JP2025020206A (ja) 2018-08-24 2024-10-25 甲状腺ホルモン受容体ベータアゴニスト化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024187991A Pending JP2025020206A (ja) 2018-08-24 2024-10-25 甲状腺ホルモン受容体ベータアゴニスト化合物

Country Status (9)

Country Link
US (2) US10800767B2 (enExample)
EP (1) EP3840755A4 (enExample)
JP (2) JP7579253B2 (enExample)
CN (1) CN112805005A (enExample)
AU (2) AU2019325656B2 (enExample)
CA (1) CA3110520A1 (enExample)
MA (1) MA53448A (enExample)
TW (1) TWI837169B (enExample)
WO (1) WO2020041741A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI884745B (zh) 2018-10-12 2025-05-21 美商拓臻股份有限公司 甲狀腺素受體β促效劑化合物
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
FI3965884T3 (fi) 2019-05-08 2025-04-02 Aligos Therapeutics Inc Thr-beetan modulaattoreita, joissa on diokso-1,2,4-triatsyylipääryhmä
WO2020228577A1 (zh) * 2019-05-10 2020-11-19 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
US12398127B2 (en) 2019-09-12 2025-08-26 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CN114437034A (zh) * 2020-11-06 2022-05-06 深圳微芯生物科技股份有限公司 一种酞嗪类化合物的可药用盐、晶型及其制备方法
AU2021377248A1 (en) 2020-11-13 2023-06-22 Inipharm, Inc. Dichlorophenol hsd17b13 inhibitors and uses thereof
CN114621207B (zh) * 2020-12-11 2025-02-11 广东东阳光药业股份有限公司 一种作为甲状腺激素β受体激动剂的化合物及其用途
EP4301357A4 (en) * 2021-03-03 2025-01-22 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CN117624073A (zh) * 2021-03-19 2024-03-01 南京明德新药研发有限公司 双环苯酚类化合物及其应用
CN117624154A (zh) * 2021-03-19 2024-03-01 南京明德新药研发有限公司 双环吡啶酮类化合物及其应用
EP4568664A1 (en) 2023-04-07 2025-06-18 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease
CN116554063B (zh) * 2023-05-23 2025-03-07 江苏省农用激素工程技术研究中心有限公司 氟胺磺隆中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7230031B2 (en) * 2002-01-30 2007-06-12 Kissei Pharmaceutical Co., Ltd. Thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
US7572799B2 (en) * 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
GB0327319D0 (en) * 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
HRP20100633T1 (hr) 2005-07-21 2011-01-31 F. Hoffmann - La Roche Ag Derivati piridazinona kao agonisti receptora tiroidnih hormona
WO2007132475A1 (en) * 2006-05-15 2007-11-22 Cadila Healthcare Limited Selective tr-beta 1 agonist
WO2008130637A1 (en) * 2007-04-18 2008-10-30 New York University Hydrazide compounds as thyroid hormone receptor modulators and uses thereof
EP3725779A4 (en) 2018-01-23 2021-02-24 Shenzhen TargetRx, Inc. SUBSTITUTED PYRIDAZINONE COMPOUND
CN113683597A (zh) 2018-06-12 2021-11-23 四川海思科制药有限公司 甲状腺激素受体激动剂及其用途
EP3864013A4 (en) 2018-10-12 2022-09-28 InventisBio Co., Ltd. Thyroid hormone receptor agonists

Similar Documents

Publication Publication Date Title
JPWO2020041741A5 (enExample)
JP6466348B2 (ja) スルファモイル−アリールアミドおよびb型肝炎を処置するための医薬品としてのその使用
CN105102451B (zh) N-苯基-氨甲酰衍生物及其作为药物用于治疗乙型肝炎的用途
JPWO2022040600A5 (enExample)
JP2020532506A5 (enExample)
JP2010540508A5 (enExample)
JP2020528889A5 (enExample)
JP2020537657A5 (enExample)
JP2020506951A5 (enExample)
JP2019512505A5 (enExample)
RU2014110623A (ru) Пирролопиразиновые ингибиторы киназы
HRP20201789T1 (hr) Antiproliferativni spojevi, te njihovi farmaceutski pripravci i uporabe
JP2016506959A5 (enExample)
HRP20230909T1 (hr) Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu
JP2014037426A5 (enExample)
HRP20240157T1 (hr) Deuterirani derivati lanifibranora
JP2019502708A5 (enExample)
HRP20240739T1 (hr) Spojevi triazolopiridinila kao inhibitori kinaze
JP2019529460A5 (enExample)
JPWO2020106642A5 (enExample)
JPWO2021041237A5 (enExample)
JPWO2021262484A5 (enExample)
MX2025010948A (es) Derivados fusionados con tiofeno sustituido, composiciones que los comprenden y su uso como productos farmacéuticos
JPWO2020119819A5 (enExample)
JP2019507116A5 (enExample)